EUVIMEDDécouvrir EUVIMED
Crossref

Multiple Chemical Class‐Based Potent VEGFR2 Inhibitors as Anticancer Therapeutics: Structure–Activity Relationship and Chemicobiological Interactions Studies

Rinki Prasad Bhagat, Ajeya Samanta, Avik Maji, Abhik Paul, Sourav Mondal, Abdul Qadir, Nikki Gupta, Balaram Ghosh, Tapan Kumar Maity

ChemMedChem · 2026-11-26 · 21 (22)

DOI: 10.1002/cmdc.70579 ↗

At a glance

Journal article in ChemMedChem, published online on 2026-11-16. Written by Rinki Prasad Bhagat and 8 co-authors. 199 references.

RésuméRéférences bibliographiquesCiteRelated studies

Abstract (original language)

Angiogenesis regulation is associated with disorders such as rheumatoid arthritis, diabetes, atherosclerosis, and cancer. Tumor development and metastasis are directly affected by tumor angiogenesis. In addition to tumor cells, host cells produce pro‐ and anti‐angiogenic molecules that regulate tumor angiogenesis. VEGFs and their receptor, VEGFR2 (KDR), strongly influence angiogenesis. When activated, KDR undergoes autophosphorylation, which ultimately promotes endothelial cell proliferation, tumor angiogenesis, tumor growth, and metastasis. Overexpression of VEGFR2 has been observed in various cancer types, including hepatocellular carcinoma, renal carcinoma, non‐small cell lung cancer, breast cancer, and cervical cancer. Researchers have developed several VEGFR2 inhibitors over the past few decades. This review examines the structure–activity relationships (SARs) of several recently developed chemical classes, including chalcones, quinazolines, pyridines, pyrimidines, thiadiazoles, indazoles, triazoles, quinoxalines, and pyrazoles, as VEGFR2 inhibitors, with an emphasis on anticancer activity. We also analyze the chemico–biological interaction profiles of several small‐molecule VEGFR2 inhibitors. This review article provides an overview of the latest advances in medicinal chemistry approaches to VEGFR2 inhibitors.

Cite

APA

Bhagat, R. P., Samanta, A., Maji, A., Paul, A., Mondal, S., Qadir, A., Gupta, N., Ghosh, B., & Maity, T. K. (2026). Multiple Chemical Class‐Based Potent VEGFR2 Inhibitors as Anticancer Therapeutics: Structure–Activity Relationship and Chemicobiological Interactions Studies. ChemMedChem, 21(22). https://doi.org/10.1002/cmdc.70579

Vancouver

Bhagat RP, Samanta A, Maji A, Paul A, Mondal S, Qadir A, et al. Multiple Chemical Class‐Based Potent VEGFR2 Inhibitors as Anticancer Therapeutics: Structure–Activity Relationship and Chemicobiological Interactions Studies. ChemMedChem. 2026;21(22). doi:10.1002/cmdc.70579

BibTeX
@article{Bhagat2026,
  author = {Bhagat, Rinki Prasad and Samanta, Ajeya and Maji, Avik and Paul, Abhik and Mondal, Sourav and Qadir, Abdul and Gupta, Nikki and Ghosh, Balaram and Maity, Tapan Kumar},
  title = {Multiple Chemical Class‐Based Potent VEGFR2 Inhibitors as Anticancer Therapeutics: Structure–Activity Relationship and Chemicobiological Interactions Studies},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {22},
  doi = {10.1002/cmdc.70579}
}
Start for free →